Sinonasal Phosphaturic Mesenchymal Tumour: Radiation Oncologist's Perspective

Overview

Journal BMJ Case Rep

Specialty General Medicine

Date 2023 Sep 18

PMID 37723097

Authors

Sudharshan Gupta

Simon Pradeep Pavamani

Affiliations

Soon will be listed here.

Abstract

Tumour-induced osteomalacia is a rare cause of osteomalacia, the majority of which is of mesenchymal origin. Oncogenic osteomalacia is a potentially curable condition caused by phosphaturic mesenchymal tumours. We present the case of a woman in her 30s with a sinonasal phosphaturic mesenchymal tumour, treated with surgical excision followed by adjuvant intensity-modulated radiotherapy and subsequent adjuvant chemotherapy. The patient experienced minimal adverse effects during radiation. There was good local control and cosmetic outcomes with no radiation-related toxicity at a follow-up period of 32 months.

References

Uramoto N, Furukawa M, Yoshizaki T . Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx. 2008; 36(1):104-5. DOI: 10.1016/j.anl.2008.01.003. View

Peters K, McLendon R, Morse M, Vredenburgh J . Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report. Case Rep Oncol. 2010; 3(1):93-97. PMC: 2918851. DOI: 10.1159/000307468. View

Shah R, Lila A, Jadhav R, Patil V, Mahajan A, Sonawane S . Tumor induced osteomalacia in head and neck region: single center experience and systematic review. Endocr Connect. 2019; 8(10):1330-1353. PMC: 6790902. DOI: 10.1530/EC-19-0341. View

Sidell D, Lai C, Bhuta S, Barnes L, Chhetri D . Malignant phosphaturic mesenchymal tumor of the larynx. Laryngoscope. 2011; 121(9):1860-3. DOI: 10.1002/lary.21916. View

Fuentealba C, Pinto D, Ballesteros F, Pacheco D, Boettiger O, Soto N . Oncogenic hypophosphatemic osteomalacia associated with a nasal hemangiopericytoma. J Clin Rheumatol. 2006; 9(6):373-9. DOI: 10.1097/01.rhu.0000101906.15276.ed. View

McCance R . Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q J Med. 2010; 16(1):33-46. View

Halperin F, Anderson R, Mulder J . Tumor-induced osteomalacia: the importance of measuring serum phosphorus levels. Nat Clin Pract Endocrinol Metab. 2007; 3(10):721-5. DOI: 10.1038/ncpendmet0639. View

Hautmann A, Hautmann M, Kolbl O, Herr W, Fleck M . Tumor-Induced Osteomalacia: an Up-to-Date Review. Curr Rheumatol Rep. 2015; 17(6):512. DOI: 10.1007/s11926-015-0512-5. View

Wasserman J, Purgina B, Lai C, Gravel D, Mahaffey A, Bell D . Phosphaturic Mesenchymal Tumor Involving the Head and Neck: A Report of Five Cases with FGFR1 Fluorescence In Situ Hybridization Analysis. Head Neck Pathol. 2016; 10(3):279-85. PMC: 4972751. DOI: 10.1007/s12105-015-0678-1. View

10.

Nitzan D, Horowitz A, Darmon D, Friedlaender M, Rubinger D, Stein P . Oncogenous osteomalacia: a case study. Bone Miner. 1989; 6(2):191-7. DOI: 10.1016/0169-6009(89)90050-0. View

11.

Tarasova V, Trepp-Carrasco A, Thompson R, Recker R, Chong W, Collins M . Successful treatment of tumor-induced osteomalacia due to an intracranial tumor by fractionated stereotactic radiotherapy. J Clin Endocrinol Metab. 2013; 98(11):4267-72. PMC: 5399525. DOI: 10.1210/jc.2013-2528. View

12.

Deep N, Cain R, McCullough A, Hoxworth J, Lal D . Sinonasal phosphaturic mesenchymal tumor: Case report and systematic review. Allergy Rhinol (Providence). 2015; 5(3):162-7. PMC: 4275463. DOI: 10.2500/ar.2014.5.0100. View

13.

Perwad F, Zhang M, Tenenhouse H, Portale A . Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol. 2007; 293(5):F1577-83. DOI: 10.1152/ajprenal.00463.2006. View

14.

Weidner N, Santa Cruz D . Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer. 1987; 59(8):1442-54. DOI: 10.1002/1097-0142(19870415)59:8<1442::aid-cncr2820590810>3.0.co;2-q. View

15.

John J, Hephzibah J, Oommen R, Shanthly N, Mathew D . Ga-68 DOTATATE Positron Emission Tomography-Computed Tomography Imaging in Oncogenic Osteomalacia: Experience from a Tertiary Level Hospital in South India. Indian J Nucl Med. 2019; 34(3):188-193. PMC: 6593943. DOI: 10.4103/ijnm.IJNM_14_19. View

16.

Folpe A, Fanburg-Smith J, Billings S, Bisceglia M, Bertoni F, Cho J . Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004; 28(1):1-30. DOI: 10.1097/00000478-200401000-00001. View

17.

Minisola S, Peacock M, Fukumoto S, Cipriani C, Pepe J, Tella S . Tumour-induced osteomalacia. Nat Rev Dis Primers. 2017; 3:17044. DOI: 10.1038/nrdp.2017.44. View

18.

Folpe A . Phosphaturic mesenchymal tumors: A review and update. Semin Diagn Pathol. 2019; 36(4):260-268. DOI: 10.1053/j.semdp.2019.07.002. View

19.

Papotti M, Foschini M, Isaia G, Rizzi G, Betts C, Eusebi V . Hypophosphatemic oncogenic osteomalacia: report of three new cases. Tumori. 1988; 74(5):599-607. DOI: 10.1177/030089168807400519. View

20.

Yoshioka K, Nagata R, Ueda M, Yamaguchi T, Konishi Y, Hosoi M . Phosphaturic mesenchymal tumor with symptoms related to osteomalacia that appeared one year after tumorectomy. Intern Med. 2006; 45(20):1157-60. DOI: 10.2169/internalmedicine.45.1797. View